(±)-Bay K 8644
L-type Ca2+ channel activator (EC50 = 17.3 nM). Has positive inotropic, vasoconstrictive and behavioral effects in vivo. Separate enantiomers (R)-(+)-Bay K 8644 and (S)-(-)-Bay K 8644 also available (Cat. Nos. 1545 and 1546 respectively). In combination with BIX-01294 (Cat. No. 3364), helps generate induced pluripotent stem cells (iPSCs) from mouse embryonic fibroblasts (MEFs). Inhibits autophagy.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 356.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.81 mL||14.03 mL||28.07 mL|
|5 mM||0.56 mL||2.81 mL||5.61 mL|
|10 mM||0.28 mL||1.4 mL||2.81 mL|
|50 mM||0.06 mL||0.28 mL||0.56 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Bourson et al (1989) Central and peripheral effects of the dihydropyridine calcium channel activator BAY K 8644 in the rat. Eur.J.Pharmacol. 160 339 PMID: 2469593
Greenberg et al (1984) Calcium channel 'agonist' BAY K 8644 inhibits calcium antagonist binding to brain and PC12 cell membranes. Brain Res. 305 365 PMID: 6204725
Shi et al (2008) Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 3 568 PMID: 18983970
Sarkar et al (2009) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 16 46 PMID: 18636076
If you know of a relevant reference for (±)-Bay K 8644, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Ca2+-channel activators L-type Calcium CaV Channels L-Type voltage-gated voltage-dependent Ca2+ (±)-BayK8644 Voltage-gated Calcium Channels
9 Citations for (±)-Bay K 8644
Citations are publications that use Tocris products. Selected citations for (±)-Bay K 8644 include:
Bellono (2017) Molecular basis of ancestral vertebrate electroreception. Nature 543 391 PMID: 28264196
Ets (2016) Sustained Contraction in Vascular Smooth Muscle by Activation of L-type Ca2+ Channels Does Not Involve Ca2+ Sensitization or Caldesmon. Front Pharmacol 7 516 PMID: 28082901
Sharma et al (2016) Suppression of protective responses upon activation of L-type voltage gated calcium channel in macrophages during mycobacterium bovis BCG infection PLoS One 11 e0163845 PMID: 27723836
Fransen et al (2015) Dissecting out the complex Ca2+-mediated phenylephrine-induced contractions of mouse aortic segments. Circ Heart Fail 10 e0121634 PMID: 25803863
Grassin-Delyle et al (2013) The expression and relaxant effect of bitter taste receptors in human bronchi. Respir Res 14 134 PMID: 24266887
Armstrong and Drapeau (2013) Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP-43 mutation in ALS. EMBO J 33 1741 PMID: 23345247
Saliba et al (2012) Activity-dependent phosphorylation of GABAA receptors regulates receptor insertion and tonic current. PLoS One 31 2937 PMID: 22531784
Subramanian and Morozov (2011) Erk1/2 inhibit synaptic vesicle exocytosis through L-type calcium channels. J Neurosci 31 4755 PMID: 21430174
Tian et al (2010) MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons. Mol Cell Neurosci 44 94 PMID: 20197093
Do you know of a great paper that uses (±)-Bay K 8644 from Tocris? If so please let us know.
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.